Which COVID-19 vaccine is best for cancer patients?

Source: www.mdanderson.org/ Author: Cynthia DeMarco With three COVID-19 vaccines now authorized for emergency use by the Food and Drug Administration (FDA), you might be wondering which vaccine is best for current and former cancer patients. After reviewing all available data, MD Anderson medical experts agree that all three vaccines are safe and recommended for cancer patients. So, should you take Johnson & Johnson’s Janssen COVID-19 vaccine (J&J), which requires only one dose, if that’s what’s available? Or should you wait for one of the Pfizer or Moderna vaccines, which both require two doses, spaced 21 and 28 days apart, respectively? According to our experts, the answer is clear: “Don’t pass up an opportunity to get the vaccine, no matter which one it is,” says Anita Ying, M.D., vice president of Ambulatory Medical Operations. “The best COVID-19 vaccine to get is the first one available to you.” Timing matters for cancer patients getting a COVID-19 vaccine Ying’s advice is particularly true for cancer patients, since some may be immunocompromised, making them both more vulnerable to severe infections and more likely to need hospitalization should they contract COVID-19. “The sooner you can start building resistance to the novel coronavirus, the sooner you’ll have at least some protection against it,” notes infectious diseases specialist David Tweardy, M.D. “And that benefits everyone.” For patients in active treatment, a COVID-19 vaccine will likely be more effective when coordinated with their treatment schedules. Those who have recently had surgery should wait two weeks before receiving one. [...]

Oral Cancer Prevention international lawsuit against Johnson & Johnson claims actions expected to cause over 7,300 oral cancers

Source: www.marketwatch.com Author: press release A lawsuit filed by Oral Cancer Prevention International (OCPI) against Johnson & Johnson in Federal Court in Trenton New Jersey claims that J&J's actions to protect the reputation of its Listerine mouthwash, which has been linked to oral cancer, can be expected to result in over 7,300 cases of otherwise preventable oral cancer across the US and over 1,120 such cancers in New York State alone. Some of the key markets impacted include: California, Colorado, Florida, Illinois, Michigan, New Jersey, Ohio, Pennsylvania, Tennessee, Texas, and Washington. "Oral cancer kills as many Americans as melanoma and twice as many as cervical cancer," says Mark Rutenberg, CEO of OCPI. "It is also rising sharply among women, young people and non-smokers. Because there has previously not been an easy way to test routine oral spots for precancerous cells, the disease is generally not detected until it is an already invasive cancer with a high mortality rate that has changed little in the last 50 years." The lawsuit, which seeks compensatory and punitive damages, claims that J&J blocked an agreement between OCPI and a then J&J subsidiary to sell its test for oral precancer. The lawsuit claims that J&J was concerned that such sales could draw attention in the $1B US Listerine market to recent studies suggesting that the mouthwash may be linked to oral cancer. J&J was particularly concerned about a 2008 study in the Australian Dental Journal -- which concluded that mouthwashes with high alcohol content could [...]

Johnson & Johnson Sued for $70 Million Over Oral Cancer Test Detection

Source: Dr.Bicuspid.com July 8, 2011 -- Oral Cancer Prevention International (OCPI), makers of the Oral CDx brush test for oral cancer detection, is suing Johnson & Johnson (J&J) over a terminated distribution contract with OraPharma. OraPharma was previously a subsidiary of J&J until it was acquired last December by Water Street Healthcare Partners, a private equity firm in Chicago. J&J, which among other things sells Listerine mouthwash, was worried that a 2008 study linking alcohol-containing mouthwashes with oral cancer would negatively affect sales of Listerine and allegedly induced OraPharma to breach the sales agreement, according to OCPI. The lawsuit, filed July 6 in U.S. District Court, District of New Jersey, claims that J&J "maliciously and fraudulently" interfered with a contract between OCPI and OraPharma that gave OraPharma exclusive rights to sell the test to U.S. dentists. J&J's interference caused OraPharma "to suppress sales of and withhold from the public a proven lifesaving oral cancer prevention product in order to protect sales of its mouthwash, Listerine, which has been linked to oral cancer," according to the complaint. After OCPI signed the contract in February 2010, J&J did not want to "lend credence to the link between Listerine and oral cancer" by selling both its mouthwash and OralCDx, the complaint states. As of press time, J&J did not return calls for comment by DrBicuspid.com. Sales of Listerine bring in more than $1 billion per year, the suit claims. OralCDx is a "quick, painless, and inexpensive test that can prevent oral cancer by [...]

J&J helps develop blood test to spot 1 cancer cell in a billion healthy ones

Source: www.therapeuticsdaily.com Author: staff A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones is moving one step closer to being available at your doctor's office. Boston scientists who invented the test and health care giant Johnson & Johnson will announce Monday that they are joining forces to bring it to market. Four big cancer centres also will start studies using the experimental test this year. Stray cancer cells in the blood mean that a tumour has spread or is likely to, many doctors believe. A test that can capture such cells has the potential to transform care for many types of cancer, especially breast, prostate, colon and lung. Initially, doctors want to use the test to try to predict what treatments would be best for each patient's tumour and find out quickly if they are working. ``This is like a liquid biopsy'' that avoids painful tissue sampling and may give a better way to monitor patients than periodic imaging scans, said Dr. Daniel Haber, chief of Massachusetts General Hospital's cancer centre and one of the test's inventors. Ultimately, the test may offer a way to screen for cancer besides the mammograms, colonoscopies and other less-than-ideal methods used now. ``There's a lot of potential here, and that's why there's a lot of excitement,'' said Dr. Mark Kris, lung cancer chief at Memorial Sloan-Kettering Cancer Center in New York. He had no role in developing the test, but Sloan-Kettering is one of [...]

Row erupts over oral cancer paper authorship

Source: www.theaustralian.news.com.au Author: Guy Healy An international expert on oral cancer withdrew from joint authorship of a paper that drew a link between the disease and the Listerine mouthwash made by his university laboratory's corporate sponsors, it has been claimed. The research paper's co-authors say Newell Johnson, whose Griffith University laboratory was funded by pharmaceutical firm Pfizer, Listerine's recent owner, decided not to put his name to the research paper, which made headlines across the world with its finding that alcohol-based mouthwashes were implicated in oral cancer. Professor Johnson says he was never an author. The claim about his involvement and withdrawal, made by Australian co-authors Michael McCullough of the University of Melbourne and Camile Farah of the University of Queensland, adds a new dimension to the controversy ignited by the paper, published in the Australian Dental Journal last December. In January UQ's head of dentistry Laurence Walsh came to the defence of mouthwashes, arguing they might prevent oral cancer, but later conceded that Listerine's present owner, Johnson & Johnson, had sponsored some of his workshops. The paper found the risk of oral cancer was increased by prolonged use of alcohol-based mouthwashes and highlighted six Listerine products. Professor McCullough said the research paper or literature review sprang from a 2007 meeting of the three researchers at a conference in Amsterdam. "After a session on the role of alcohol in oral cancer, we ended up deciding that we would formally write this article and review it between the three of us," [...]

2009-02-19T05:17:09-07:00February, 2009|Oral Cancer News|
Go to Top